Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Prometheus Biosciences $218.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Evernorth acquisition of MDLIVE
We are advising MDLIVE on the transaction
Reckitt Benckiser Group acquisition of Biofreeze
We are advising RB on the acquisition
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Signify Health $648.6 million IPO
We advised Signify Health on its IPO and NYSE listing
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing